Fortis Healthcare Ltd: A Deep Dive into India's Second-Largest Hospital Chain

Fortis Healthcare Ltd (NSE: FORTIS) stands as one of India's most prominent integrated healthcare service providers, operating at the intersection of hospital care and diagnostics. Backed by IHH Healthcare Berhad — Malaysia's largest healthcare group and one of Asia's leading private healthcare operators — Fortis has transformed itself from a debt-laden, governance-troubled entity into a steadily compounding healthcare powerhouse. This comprehensive equity research report examines Fortis Healthcare's business model, financial performance, valuation, peer positioning, and investment thesis.

Company Overview

Fortis Healthcare Ltd (FHL) was incorporated in February 1996, and the company's first healthcare facility became operational in Mohali, Punjab in 2001. Over the past two decades, Fortis has grown into a leading integrated healthcare delivery platform spanning three countries — India, Nepal, Dubai, and Sri Lanka — operating 36 healthcare facilities with approximately 4,000 operational beds.

The company operates through two primary business verticals:

• Hospital Segment: Multi-specialty and super-specialty hospitals providing inpatient and outpatient treatments across various medical disciplines including cardiac sciences, orthopaedics, neurosciences, oncology, renal sciences, and organ transplants.
• Diagnostics Segment: Through its 57% owned subsidiary SRL Limited, Fortis controls one of India's largest private diagnostics chains. SRL has a presence in over 600 cities and towns, with 415 laboratories, 8,200 direct clients, and 1,400 collection centres.

The strategic backing of IHH Healthcare (Malaysia), which holds approximately 31.17% of Fortis's equity, provides the company with global healthcare expertise, operational know-how, and financial stability. IHH Healthcare is one of the world's largest private healthcare groups by market capitalisation, operating across 80 hospitals in 10 countries.

Key Financial Metrics at a Glance

As of June 1, 2026, Fortis trades at ₹929 per share, placing its market capitalisation at approximately ₹70,151 crore. The stock has traded in a 52-week range of ₹723 to ₹1,105, indicating a volatility band of roughly 53%. The current price sits approximately 16% below its 52-week high and 28% above its 52-week low.

Historical Financial Performance

Revenue Growth: Consistent Double-Digit Expansion

Fortis has demonstrated remarkable revenue growth over the past decade, with consolidated annual sales growing from ₹3,966 crore in FY2015 to ₹9,128 crore in FY2026 — a 130% increase over 11 years. More impressively, the growth trajectory has accelerated significantly in recent years:

The compounded sales growth stands at 8% over 10 years, 18% over 5 years, 13% over 3 years, and 17% on a trailing twelve-month (TTM) basis. The post-COVID acceleration — from ₹4,030 crore in FY2021 to ₹9,128 crore in FY2026 — represents a 126% increase in just five years, reflecting both organic capacity expansion and the structural demand tailwind for quality healthcare in India.

Profitability: From Losses to Industry-Leading Margins

Perhaps the most striking aspect of Fortis's financial transformation is its profitability trajectory. The company reported a net loss of ₹130 crore in FY2015 and ₹934 crore in FY2018 (impacted by exceptional items related to the Singh brothers' legacy issues), but has since turned consistently profitable:

The operating profit margin (OPM) has expanded from a meagre 2-3% in FY2015-16 to a robust 23% in FY2026 — a dramatic improvement reflecting operating leverage, improved case mix, and better cost management. Net profit margins have similarly expanded, with FY2026 recording a net profit of ₹1,064 crore versus a net loss of ₹130 crore just eleven years ago.

The profit CAGR metrics are particularly impressive: 60% over 10 years, 64% over 5 years, 27% over 3 years, and 26% on a TTM basis. The 5-year profit CAGR of 64.4% is among the highest in the Indian hospital sector.

Quarterly Performance: FY2026 Shows Strong Momentum

The quarterly progression over the last fiscal year demonstrates consistent execution:

Q2 FY2026 was the standout quarter, delivering a net profit of ₹329 crore (the highest quarterly profit in the company's history) on revenues of ₹2,331 crore with an OPM of 24%. The Q4 FY2026 revenue of ₹2,365 crore represents the highest quarterly top-line figure, indicating continued growth momentum entering FY2027.

Year-over-year, Q4 FY2026 saw 17.8% sales growth and 22.4% profit growth versus Q4 FY2025, indicating healthy organic growth rates.

Balance Sheet Analysis: Strengthening with a Caveat

Assets and Liabilities

The balance sheet has expanded significantly, with total assets growing from ₹7,592 crore in FY2015 to ₹15,966 crore in FY2026 — a 110% increase. Fixed assets have grown to ₹12,232 crore, reflecting heavy capital expenditure on new hospital capacity and brownfield expansions.

The net worth (Equity + Reserves) stands at approximately ₹9,896 crore as of FY2026, up from ₹4,048 crore in FY2015 — a 144% improvement in the company's equity base.

However, a notable concern is the increase in borrowings, which have risen from ₹1,155 crore in FY2024 to ₹3,473 crore in FY2026 — a 200% increase in two years. This elevated debt is largely attributable to the acquisition-driven growth strategy and capital expenditure on new hospital facilities. The debt-to-equity ratio stands at approximately 0.35x, which remains comfortable but warrants monitoring.

Capacity Expansion and CWIP

The capital work-in-progress (CWIP) of ₹432 crore as of FY2026 indicates ongoing expansion projects. Fortis has been actively investing in:

• Brownfield expansion at existing hospitals (adding beds at Fortis Memorial Research Institute, Gurugram; Fortis Hospital, Bannerghatta Road; and others)
• Greenfield projects in under-penetrated geographies
• Diagnostics infrastructure through SRL Limited

The total fixed assets plus CWIP of ₹12,664 crore represents the company's investment in physical healthcare infrastructure.

Cash Flow Analysis: Strong Internal Accruals

Cash flow from operations (CFO) has grown from a meagre ₹24 crore in FY2015 to a robust ₹1,601 crore in FY2026 — reflecting the company's improving earnings quality. The CFO-to-operating-profit ratio averaging around 90-100% in recent years indicates that reported profits are being largely converted into cash.

Free cash flow (FCF) of ₹673 crore in FY2026 — while lower than operating cash flow due to significant capex — demonstrates that the company is generating surplus cash after all maintenance and growth investments. The cumulative FCF over the last four years (FY2023-FY2026) totals approximately ₹1,803 crore, providing a healthy buffer against the rising debt levels.

Key Efficiency Ratios

Working Capital Management

Fortis operates with a negative cash conversion cycle of -99 days as of FY2026, which is a highly favourable working capital characteristic. This means the company collects from patients/insurers faster than it pays suppliers, effectively financing its operations through negative working capital — a hallmark of well-run hospital businesses.

Return Ratios

The ROCE of 13.5% and ROE of 11.3% represent significant improvement from the historical averages, though they remain below the levels of the best-in-class peers like Apollo Hospitals (ROCE 17.89%). The ROCE has improved consistently from near-zero levels in FY2015 to 13% in FY2026, indicating improving capital efficiency.

However, it is worth noting that the 3-year average ROE of 9.88% is flagged as a concern by Screener.in's automated analysis, as it falls below the typical threshold for quality companies.

Shareholding Pattern: Institutional Confidence Growing

Current Shareholding (Q4 FY2026 / March 2026)

The shareholding pattern reveals several noteworthy trends:

1. Promoter holding stable at 31.17%: IHH Healthcare's stake has remained unchanged at 31.17% since Q1 FY2021, indicating a long-term commitment to the Indian market. The open offer regulatory cap currently limits IHH from increasing its stake further without triggering SEBI's mandatory open offer provisions.

2. DII holding at all-time high of 31.35%: Domestic institutional investors — primarily mutual funds and insurance companies — have steadily increased their stake from 0.4% in FY2017 to 31.35% in FY2026. This rising DII conviction signals institutional belief in Fortis's long-term growth story.

3. FII holding moderated to 25.98%: Foreign institutional investors have reduced their stake from a peak of 45.63% in FY2018 to 25.98% in FY2026, though it has stabilised in the 25-28% range over the past two years.

4. Retail holding declining to 11.50%: The public/retail holding has decreased from 31.69% in FY2018 to just 11.50% in FY2026, indicating that retail investors have been gradually exiting as institutional ownership has increased. The total number of shareholders stands at 2,26,685.

Peer Comparison: Fortis in the Hospital Sector Hierarchy

Fortis operates in India's highly competitive private hospital sector. Here's how it compares with its listed peers:

Key Peer Observations:

1. Third-largest by market cap: At ₹70,151 crore, Fortis is the third-largest listed hospital chain in India, behind Apollo Hospitals (₹1,16,588 crore) and Max Healthcare (₹91,334 crore).

2. Premium valuation: Fortis trades at a P/E of 66.3x, which is higher than Apollo Hospitals (59.6x), Max Healthcare (61.6x), Narayana Hrudayalaya (45.7x), and Global Health (56.4x). Only Aster DM (91.5x) and Krishna Institute (121.6x) command higher P/E multiples.

3. Strong quarterly revenue: Fortis's quarterly revenue of ₹2,365 crore is the second-highest among listed hospital chains, behind only Apollo Hospitals (₹6,606 crore).

4. ROCE below leaders: Fortis's ROCE of 13.47% lags behind Apollo Hospitals (17.89%), Global Health (17.14%), Max Healthcare (14.72%), and Narayana Hrudayalaya (15.36%), suggesting room for improvement in capital efficiency.

5. Median sector metrics: The hospital sector (30 companies) shows median metrics of P/E 45.7x, Market Cap ₹3,833 crore, and ROCE 14.69%, indicating that Fortis trades at a premium to sector medians on most metrics.

Valuation Analysis: Is the Premium Justified?

Price-to-Earnings (P/E)

At 66.3x trailing earnings, Fortis commands a significant premium to the broader market (Nifty 50 P/E ~22x) and even to the hospital sector median (45.7x). However, the premium appears partially justified by:

• Earnings growth visibility: With a 5-year profit CAGR of 64.4% and management guiding for continued capacity additions, the PEG ratio (Price/Earnings-to-Growth) is approximately 1.0x (66.3 P/E ÷ 64% growth), which is reasonable for a high-quality healthcare compounder.
• Structural demand tailwind: India's private healthcare market is expected to grow at 12-15% CAGR over the next decade, driven by rising incomes, insurance penetration, and an ageing population.
• IHH backing: The strategic parentage provides an implicit floor on valuations and reduces corporate governance risks.

Price-to-Book (P/B)

At 7.09x book value (CMP ₹929 vs Book Value ₹131), Fortis trades at a premium, but this is largely in line with high-quality hospital chains that generate superior returns on equity over time.

EV/EBITDA

Based on an EBITDA of approximately ₹2,085 crore (operating profit for FY2026) and an enterprise value of roughly ₹73,000 crore (market cap + net debt), the EV/EBITDA works out to approximately 35x — in line with premium hospital valuations in India.

Strengths and Investment Positives

1. Exceptional profit growth: 64.4% profit CAGR over 5 years is among the best in the Indian healthcare sector, demonstrating strong operating leverage and improved case mix.

2. Improving operating margins: OPM has expanded from 3% in FY2015 to 23% in FY2026, reflecting the benefits of scale, better revenue management, and operational efficiencies.

3. Strong parentage: IHH Healthcare's 31.17% stake provides global expertise, financial backing, and a potential pathway to further consolidation in Indian healthcare.

4. Diagnostics diversification: SRL Limited's 415 laboratories across 600+ cities provide a complementary revenue stream with better capital efficiency than hospital operations.

5. Robust cash generation: Operating cash flow of ₹1,601 crore and free cash flow of ₹673 crore in FY2026 demonstrate high earnings quality.

6. Negative working capital cycle: The cash conversion cycle of -99 days means the company effectively receives supplier financing, a structural advantage of hospital businesses.

7. Consistent institutional buying: DII holding has increased to an all-time high of 31.35%, reflecting strong institutional conviction.

8. Diversified geographic presence: Operations across 36 facilities in India, Nepal, Dubai, and Sri Lanka reduce concentration risk.

9. Accelerating revenue growth: FY2026 revenue growth of 17.3% is the fastest in four years, indicating improving demand momentum.

10. EPS growth trajectory: Earnings per share have grown from ₹7.80 in FY2023 to ₹13.80 in FY2026 — a 77% increase in three years.

Risks and Concerns

1. Elevated valuation: At 66.3x P/E, the stock is priced for perfection. Any earnings miss could trigger a significant correction.

2. Rising debt levels: Borrowings have increased from ₹1,155 crore in FY2024 to ₹3,473 crore in FY2026 — a 200% increase in two years. While the debt-to-equity ratio of 0.35x remains manageable, the trajectory needs monitoring.

3. Low historical ROE: The 3-year average ROE of 9.88% is below the cost of equity, indicating that the company has not always created value for shareholders.

4. Regulatory risks: The Indian government's push for healthcare price regulation (including caps on stent and knee implant prices) could impact hospital profitability over time.

5. Competitive intensity: The hospital sector is witnessing aggressive expansion by Apollo Hospitals, Max Healthcare, Narayana Hrudayalaya, and new entrants like Manipal-AMRI, which could pressure pricing and occupancy rates.

6. Promoter stake overhang: The uncertainty around whether IHH will increase its stake (requiring an open offer) or maintain status quo creates potential overhang.

7. Dividend yield of just 0.11%: With a dividend of only ₹1 per share (7% payout ratio), the stock offers minimal income and is entirely dependent on capital appreciation.

8. Interest cost rising: Interest expenses have increased from ₹131 crore in FY2024 to ₹314 crore in FY2026 — a 140% increase that could compress net margins if interest rates remain elevated.

9. Q3 FY2026 profit dip: The quarterly profit of ₹197 crore in Q3 FY2026 was the lowest in four quarters, indicating some lumpiness in earnings.

10. Premium to book value at 7.09x limits the margin of safety in a downside scenario.

Dividend Policy and Capital Allocation

Fortis has adopted a conservative dividend policy, with the payout ratio averaging 7-13% over the past four years:

The ₹1 per share final dividend for FY2026 was approved by the board on May 22, 2026, along with the appointment of a cost auditor and adoption of a CSR policy. The low dividend payout is typical of growth-stage hospital companies that prefer to reinvest cash flows into capacity expansion.

Recent Developments and Corporate Actions

Several recent developments are worth noting:

1. Q4 FY2026 results announced May 22, 2026: Revenue of ₹2,365 crore, operating profit of ₹532 crore (23% OPM), and net profit of ₹271 crore (EPS ₹3.52).

2. ₹1 final dividend recommended for FY2026.

3. Earnings call transcript released on May 29, 2026, providing management commentary on growth outlook.

4. Annual Secretarial Compliance Report filed on May 29, 2026.

5. CRISIL rating updates maintained with stable outlook, reflecting improving credit profile.

6. Investor meet held on May 25, 2026 to discuss Q4/FY2026 audited results, with audio recording available online.

7. Newspaper publications filed on May 23, 2026 as required under SEBI LODR regulations.

Technical Outlook

At ₹929, the stock is trading approximately:

• 16% below its 52-week high of ₹1,105
• 28% above its 52-week low of ₹723
• Near the midpoint of its 52-week range

The stock price CAGR metrics are:

• 10 Years: 19%
• 5 Years: 33%
• 3 Years: 50%
• 1 Year: 29%

The 50% CAGR over 3 years reflects the massive re-rating the stock has undergone as the market priced in improving fundamentals. The 1-year return of 29% remains solid but suggests the easy re-rating phase may be behind us.

Investment Thesis: Quality Healthcare at a Premium

Bull Case (Target: ₹1,100-1,200)

• Revenue growth sustains at 15-18% CAGR over FY2027-FY2029
• OPM improves to 24-25% as new beds reach optimal occupancy
• Net profit reaches ₹1,500-1,800 crore by FY2029
• P/E multiple sustains at 60-65x given sector premium
• IHH increases stake, triggering an open offer at premium

Base Case (Target: ₹850-1,000)

• Revenue grows at 12-15% CAGR with stable margins
• Net profit reaches ₹1,200-1,400 crore by FY2028
• P/E compresses to 55-60x as growth normalises
• Stock delivers 10-15% annual returns from current levels

Bear Case (Target: ₹600-750)

• Regulatory headwinds compress margins
• Rising debt leads to higher interest costs
• P/E de-rates to 40-45x on growth concerns
• Stock corrects 20-35% from current levels

Conclusion

Fortis Healthcare has undergone a remarkable transformation from a governance-challenged, loss-making entity to a ₹70,000 crore healthcare powerhouse delivering ₹1,000 crore+ in annual profits. The 5-year profit CAGR of 64.4%, expanding operating margins from 3% to 23%, and improving return ratios paint a picture of a company in the sweet spot of India's healthcare growth story.

However, at 66.3x earnings and 7.09x book value, the stock is not cheap. The rising debt levels (borrowings tripled to ₹3,473 crore in two years), sub-10% average ROE, and intense competitive landscape are genuine concerns that investors must weigh against the structural growth opportunity.

For long-term investors with a 3-5 year horizon, Fortis represents a quality healthcare compounder backed by a strong global parent (IHH Healthcare), operating in a sector with secular demand tailwinds. The key is whether the company can sustain its current growth trajectory and improve return ratios to justify the premium valuation.

At current levels, Fortis is a "buy on dips" candidate — accumulating on corrections toward the ₹800-850 range would offer a better risk-reward profile than chasing at current levels. The ₹1,100 level (52-week high) represents a near-term resistance, while ₹720-750 provides strong support based on historical price action.